| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_151315817545d6123e456bf8d2a6553b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03691c78c0133438617c21ecd2b82b73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54e26599697c339c3a7a9169043255d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d5dd9e93e7d51a235fe63e844e6d6fe |
| publicationDate |
2022-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114929343-A |
| titleOfInvention |
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies |
| abstract |
B cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods of treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T through the CD3 complex in the presence of BCMA-expressing tumor cells cell. In certain embodiments, the bispecific antigen binding molecules of the invention are capable of inhibiting the growth of BCMA-expressing tumors. |
| priorityDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |